<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although oral <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> are the treatment of choice for moderate to severe ulcerative <z:e sem="disease" ids="C0868908" disease_type="Disease or Syndrome" abbrv="">pancolitis</z:e>, their systemic side effects and <z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">adrenal suppression</z:e> account for considerable morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>An oral <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi>-conjugate (<z:chebi fb="0" ids="50266">prodrug</z:chebi>), <z:chebi fb="0" ids="3207">budesonide</z:chebi>-beta-D-<z:chebi fb="0" ids="24302">glucuronide</z:chebi>, which is not absorbed in the small intestine but is hydrolysed by colonic <z:mp ids='MP_0001794'>bacterial</z:mp> and mucosal beta-glucuronidase to release free <z:chebi fb="0" ids="3207">budesonide</z:chebi> into the colon was synthesised </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to compare treatment with <z:chebi fb="0" ids="3207">budesonide</z:chebi>-beta-D-<z:chebi fb="0" ids="24302">glucuronide</z:chebi> with treatment with free <z:chebi fb="0" ids="3207">budesonide</z:chebi> by examining: (1) the healing of experimental <z:hpo ids='HP_0002583'>colitis</z:hpo> and (2) the extent of <z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">adrenal suppression</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0868908" disease_type="Disease or Syndrome" abbrv="">Pancolitis</z:e> was induced with 4% <z:chebi fb="22" ids="15366">acetic acid</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Animals were then randomised to receive oral therapy for 72 hours with (1) <z:chebi fb="0" ids="3207">budesonide</z:chebi>-beta-D-<z:chebi fb="0" ids="24302">glucuronide</z:chebi>, (2) free <z:chebi fb="0" ids="3207">budesonide</z:chebi>, or (3) vehicle </plain></SENT>
<SENT sid="5" pm="."><plain>Drug efficacy and colitic healing was determined by measuring gross colonic ulceration, myeloperoxidase activity, and in vivo colonic fluid absorption </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">Adrenal suppression</z:e> was determined by measuring plasma adrenocorticotrophic hormone and serum <z:chebi fb="0" ids="16827">corticosterone</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Vehicle-treated <z:hpo ids='HP_0002583'>colitis</z:hpo> animals had gross ulceration, increased myeloperoxidase activity, and net colonic fluid secretion </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment with oral <z:chebi fb="0" ids="3207">budesonide</z:chebi>-beta-D-<z:chebi fb="0" ids="24302">glucuronide</z:chebi> accelerated <z:hpo ids='HP_0000001'>all</z:hpo> measures of <z:hpo ids='HP_0002583'>colitis</z:hpo> healing at a fourfold lower dose than did free <z:chebi fb="0" ids="3207">budesonide</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, treatment with <z:chebi fb="0" ids="3207">budesonide</z:chebi>-beta-D-<z:chebi fb="0" ids="24302">glucuronide</z:chebi> did not result in <z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">adrenal suppression</z:e> whereas free <z:chebi fb="0" ids="3207">budesonide</z:chebi> treatment did </plain></SENT>
<SENT sid="10" pm="."><plain>A newly synthesised orally administered <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi>-conjugate accelerates <z:hpo ids='HP_0002583'>colitis</z:hpo> healing with limited <z:e sem="disease" ids="C0271738" disease_type="Disease or Syndrome" abbrv="">adrenal suppression</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Development of an orally administered colon-specific steroid delivery system represents a novel approach to <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> treatment </plain></SENT>
</text></document>